SCL사이언스

246960KOSDAQ의료용품 및 기타 의약 관련제품 제조업

40.5 / 100

Reference Date: 2026-04-13

Financial Score13.5 / 40

News Sentiment16.0 / 25

Momentum7.0 / 20

Disclosure4.0 / 15

AI Analysis: the high debt ratio poses financial risk, ROE is below the industry average. Rose 8.8% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

SCL Science is a company specializing in protein-based platform technologies, offering hemostatic products, bio-logging services, and healthcare data platforms. In 2025, its consolidated sales reached 22,011 million KRW, reflecting a 365% increase driven by growth in bio-logging and data platform services. Key products include the 'InnoSEAL' hemostatic series, 'InTro' catheters, and AI-powered medical data solutions, with expansion into high-risk medical device markets and global bio-logging services.

Number of Employees

163people

Average Salary

77.3M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 19.894.0Point

PBR

3.21Industry Average 1.621.0Point

2.0x industry avg (risky)

ROE

-21.12Industry Average -4.893.5Point

4.3x industry avg (excellent)

Debt Ratio

134.87Industry Average 8.880.0Point

15.2x industry avg (risky)

Trend 2023~20255.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲311.5% (2-year basis)

Operating Profit Growth Rate

2.0 / 3

Avg ▲8.0% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -24.7% (improving, 3yr)

Detailed News Sentiment

9 totalPositive 5Neutral 0Negative 0Average Sentiment Score 75

Positive
SCL사이언스, AI 기반 항암 방향성 제시… 챗GPT 방식 단백질 모...
SCL사이언스 자회사 네오젠로직이 대한진단면역학회에서 AI 기반 항암 백신 모델 '딥네오'와 최신 연구 성과를 발표하며 항암 방향성을 제시했다는 소식입니다.
Positive
SCL사이언스 "2대주주 주주제안 철회로 경영권 안정 확보"
SCL사이언스가 2대주주의 감사선임 관련 주주제안 철회로 경영권 안정성을 확보했다는 소식입니다.
Positive
네오젠로직, 항암 백신 AI모델 ‘딥네오’ 발표
네오젠로직이 대한진단면역학회 춘계학술대회에서 최초로 언어모델을 적용한 신생암항원 발굴 인공지능(AI) 모델 '딥네오'를 소개했다는 소식입니다.

Detailed Momentum

52-week position1.0Point

Near 52w low (19%, downtrend)

Current 2,220Won52-week high 4,04052-week low 1,774

1-month return5.0Point

1m +8.82% (rising)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

12 totalPositive 0Neutral 10Negative 2

Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-31
Neutral정기주주총회결과2026-03-31
Negative소송등의제기ㆍ신청(경영권분쟁소송) (의안상정가처분)2026-03-30
Neutral사업보고서 (2025.12)2026-03-23
Neutral감사보고서제출2026-03-23